Actinium Pharmaceuticals (NYSE:ATNM) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a research report sent to investors on Monday morning.

Other equities analysts have also recently issued reports about the stock. B. Riley cut shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $16.00 to $2.00 in a research note on Wednesday, August 7th. HC Wainwright lowered their price target on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Maxim Group reduced their price target on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.40.

Actinium Pharmaceuticals Trading Up 1.0 %

ATNM opened at $1.94 on Monday. Actinium Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $10.24. The firm’s 50 day moving average is $1.80. The stock has a market cap of $60.53 million, a P/E ratio of -1.28 and a beta of 0.14.

Institutional Investors Weigh In On Actinium Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company purchased a new position in Actinium Pharmaceuticals during the second quarter worth about $92,000. Renaissance Technologies LLC purchased a new position in shares of Actinium Pharmaceuticals during the 2nd quarter worth about $142,000. Interchange Capital Partners LLC acquired a new stake in shares of Actinium Pharmaceuticals in the third quarter worth approximately $37,000. Rhumbline Advisers grew its holdings in Actinium Pharmaceuticals by 23.4% in the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after purchasing an additional 7,525 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Actinium Pharmaceuticals during the second quarter worth approximately $356,000. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).